BSE filing, NSE: SAMPANN. Summary written from the filing by ALFA Finder's alert engine.
Sampann Utpadan India Ltd: key numbers
- Share price
- ₹22.54
- Market cap
- ₹110.0 Cr
- Revenue (annual)
- ₹142.6 Cr
- Net profit (annual)
- ₹6.78 Cr
- P/E (TTM)
- 15.7×Sector 31.4×
- Promoter holding
- 40.39%-0.27% QoQ
- FII holding
- 17.25%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sampann Utpadan India Ltd
All →Sampann Utpadan India Board Meeting Date
Sampann Utpadan India has scheduled a board meeting for November 5, 2026 to consider unaudited standalone and consolidated results for the quarter ended September 30, 2026. The trading window stays closed until 48 hours after the results are made public.
Sampann Utpadan India Legal & Regulatory
The NSE has waived the fine previously levied on Sampann Utpadan India Limited for a delay in filing a trading approval application.
Sampann Utpadan India Management Change
Sampann Utpadan India Limited has appointed V Doogar & Associates as its new statutory auditor, effective September 29, 2026, for a 60-month term.
Sampann Utpadan India Annual General Meeting
Sampann Utpadan India Limited conducted its 16th Annual General Meeting on September 29, 2026. Shareholders transacted business including the adoption of financial statements and auditor appointments.
Sampann Utpadan India Annual General Meeting
Sampann Utpadan India Limited has issued a notice for its 16th Annual General Meeting scheduled for September 29, 2026. Key agenda items include adopting financial statements and auditor appointments.
Sampann Utpadan India Annual Report
Sampann Utpadan India Limited released its 16th Annual Report for FY 2025-26. The company reported consolidated annual revenue of ₹134.69 crore, marking a 45.06% growth.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.